CARL - Carlsmed, Inc. News

Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $20

Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises

seekingalpha.com

Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript

marketbeat.com

Carlsmed Q2 Earnings Call Highlights

Carlsmed NASDAQ: CARL reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 milli

Carlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue Estimates

Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus E

Carlsmed Raises FY2026 Sales Guidance from $72.000M-$77.000M to $74.000M-$78.000M vs $74.830M Est

Carlsmed (NASDAQ:CARL) raises FY2026 sales outlook from $72.000 million-$77.000 million to $74.000 m

Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance

Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026

Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures

Centers for Medicare & Medicaid Services (CMS) Fiscal Year 2027 Inpatient Final Rule creates three n

Carlsmed, Inc. To Participate in Upcoming Investor Conferences

CARLSBAD, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the

Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026

CARLSBAD, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular sess

Needham Initiates Coverage On Carlsmed with Buy Rating, Announces Price Target of $17

Needham analyst David Saxon initiates coverage on Carlsmed (NASDAQ:CARL) with a Buy rating and an

Wall Street Analysts See a 51.94% Upside in Carlsmed, Inc. (CARL): Can the Stock Really Move This Hi

The consensus price target hints at a 51.9% upside potential for Carlsmed, Inc. (CARL). While empiri

seekingalpha.com

Carlsmed, Inc. (CARL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Wall Street Analysts Think Carlsmed, Inc. (CARL) Could Surge 90.77%: Read This Before Placing a Bet

The mean of analysts' price targets for Carlsmed, Inc. (CARL) points to a 90.8% upside in the stock.

seekingalpha.com

Carlsmed, Inc. (CARL) Q1 2026 Earnings Call Transcript

Carlsmed, Inc. (CARL) Reports Q1 Loss, Tops Revenue Estimates

Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus E

Carlsmed Q1 2026 Earnings Call: Complete Transcript

Carlsmed Raises FY2026 Sales Guidance from $70.000M-$75.000M to $72.000M-$77.000M vs $72.807M Est

Carlsmed (NASDAQ:CARL) raises FY2026 sales outlook from $70.000 million-$75.000 million to $72.000 m

Carlsmed Q1 EPS $(0.32) Beats $(0.41) Estimate, Sales $16.100M Beat $14.984M Estimate

Carlsmed (NASDAQ:CARL) reported quarterly losses of $(0.32) per share which beat the analyst consens

Carlsmed® Reports First Quarter 2026 Financial Results

First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 r

Earnings Scheduled For May 5, 2026

Carlsmed, Inc. To Participate in Upcoming Investor Conferences

CARLSBAD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or th

Carlsmed Showcases Personalized Spine Fusion Gains, Cervical Expansion and Medicare Tailwinds at Nee

Carlsmed (NASDAQ: CARL) used its presentation at Needham's 25th Annual Healthcare Conference to high

Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026

CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical techno

Comparing MiniMed Group (NASDAQ:MMED) and Carlsmed (NASDAQ:CARL)

Carlsmed (NASDAQ: CARL - Get Free Report) and MiniMed Group (NASDAQ: MMED - Get Free Report) are bot

Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference

CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or th

Financial Contrast: Carlsmed (NASDAQ:CARL) & Predictive Oncology (NASDAQ:AGPU)

Carlsmed (NASDAQ: CARL - Get Free Report) and Predictive Oncology (NASDAQ: AGPU - Get Free Report) a

Contrasting Carlsmed (NASDAQ:CARL) and Medline (NASDAQ:MDLN)

Medline (NASDAQ: MDLN - Get Free Report) and Carlsmed (NASDAQ: CARL - Get Free Report) are both manu

Earnings Scheduled For February 25, 2026

Earnings Scheduled For November 6, 2025